Elucidation and application of the mechanism of synergistic healing-promoting effects of amelogenin and teprenone.

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K21089
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0907:Oral science and related fields
• Research Institution: Kyushu University
• Principal Investigator: Yamato Hiroaki 九州大学, 歯学研究院, 共同研究員 (50906336)
• Project Period (FY): 2021-08-30 – 2023-03-31
• Keywords: アメロジェニン / テプレノン / GRP78 / 血管新生 / 創傷治癒

Outline of Final Research Achievements

When periodontal ligament cells were stimulated with teprenone, the secretion of angptl4 which has angiogenic activity, and amphiregulin which is a member of the epidermal growth factor family was confirmed. In addition, the production of IL-8, MCP-1, and IL-6, which are angiogenesis-inducing factors, was confirmed in the teprenone + amelogenin combination stimulation group compared with the teprenone single stimulation group. tube formation was induced. In other words, it was suggested that combined stimulation of teprenone and amelogenin strongly promotes periodontal ligament migration, and further induces wound healing and angiogenesis.

Free Research Field

歯周病学分野

Academic Significance and Societal Importance of the Research Achievements

本研究によりテプレノン・アメロジェニンによる組織再生のメカニズムが証明されることで、安価かつ安全な歯周組織再生薬によって医療福祉政策に大きく貢献する。さらに、血管新生薬や治癒促進剤等として医科領域まで適応範囲を拡げることができれば、医療費の抑制にも繋がる。実際に、アメロジェニンは褥瘡性潰瘍治療薬(Xelma)として既に用いられているが、テプレノンによる増強作用が証明されれば、これにとって代わる難治性潰瘍治療薬となる可能性がある。